Hjem › Lungekreft › Oregon
Kliniske studier for Lungekreft i Oregon
31 studier for Lungekreft søker deltakere på steder i Oregon.
Byer i Oregon
Offisiell studietekst (engelsk)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Good Samaritan Hospital, Corvallis
- Three Rivers Community Hospital, Grants Pass
- Asante Rogue Regional Medical Center, Medford
- og 4 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- og 7 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Providence Portland Medical Center ( Site 0043), Portland
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059), Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07286149Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
RekruttererFase 3
Alder 70 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Oncology Associates of Oregon PC, Eugene
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07127874A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Oregon Health and Science University ( Site 0052), Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C, Happy Valley
- Northwest Cancer Specialists, P.C., Portland
- Northwest Cancer Specialists, P.C, Tigard
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07222566A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06618287A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07063745Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07100080Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Oregon Health and Science University, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Oncology Associates of Oregon, Eugene
- Asante Rogue Regional Medical Center, Medford
- Providence Portland Medical Center, Portland
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- USOR - Oncology Associates of Oregon, P.C, Eugene
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06343402Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Legacy Mount Hood Medical Center, Gresham
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Legacy Meridian Park Hospital, Tualatin
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05624996A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Providence Portland Medical Center, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT05652686Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- Willamette Valley Cancer Institute and Research Center, Eugene
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2026 · NCT07315113Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Oregon Health and Science University, Portland
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 26. jun. 2026 · NCT04614103Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
- OHSU Knight Cancer Institute, Portland
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT07405086Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- og 4 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572MYLUNG Consortium Part 3: Observational Study
- Willamette Valley Cancer Institute and Research Center, Eugene
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT05885698Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- og 4 flere
RekruttererFase 2
18 Minutes · Alle kjønn · Oppdatert 5. mai 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- og 5 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT06616584cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- og 1 flere
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jan. 2026 · NCT06073431SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Oregon Health & Science University, Portland
RekruttererObservasjonsstudie
Alder 50 og eldre · Alle kjønn · Oppdatert 5. aug. 2025 · NCT06122077Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.